Literature DB >> 22033700

Is intraoperative confirmation of malignancy during pancreaticoduodenectomy mandatory?

Giuseppe Garcea1, Matthew S Metcalfe, David P Berry, Gavin S Robertson, David M Lloyd, Ashley R Dennison.   

Abstract

INTRODUCTION: Differentiating between chronic pancreatitis and pancreatic adenocarcinoma can be difficult due to considerable overlap in disease presentation and radiological signs and the frequent co-existence of the two conditions. In this situation, surgeons may have to proceed to "blind" pancreaticoduodenectomy or attempt to confirm malignancy intraoperatively with frozen section (FS) histology.
METHODS: This study attempted to ascertain the false-negative and false-positive rates of undertaking pancreaticoduodenectomies (PD) based on clinical suspicion (CS) or after intraoperative confirmation of malignancy using FS histology.
RESULTS: Of patients, 13.6% (nine out of 66) underwent a benign PD in the CS group; 6.7% of patients had a missed malignancy in the FS group (n = 62), but intraoperative histology prevented PD in 35% of patients with benign disease in the FS group. Specificity and sensitivity of intraoperative FS in detecting malignancy was 100% and 89.7%, respectively. Sensitivity of clinical assessment in detecting malignancy was 86.4%.
CONCLUSIONS: In experienced hands, intraoperative confirmation of malignancy is effective and will avoid resection in patients with benign disease. However, for many surgeons the chance of missing a small tumour with a false-negative biopsy will be unacceptable and they would prefer to undertake a "blind" resection and accept the mortality risk of pancreaticoduodenectomy for benign disease.

Entities:  

Mesh:

Year:  2011        PMID: 22033700     DOI: 10.1007/s11605-011-1728-y

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  20 in total

1.  Initial and long-term outcome after palliative surgical drainage of 269 patients with malignant biliary obstruction.

Authors:  K F D Kuhlmann; D van Poll; S M M de Castro; N T van Heek; O R C Busch; T M van Gulik; H Obertop; D J Gouma
Journal:  Eur J Surg Oncol       Date:  2007-01-09       Impact factor: 4.424

2.  Combined biliary and gastric bypass procedures as effective palliation for unresectable malignant disease.

Authors:  Christopher D Mann; Sarah C Thomasset; Nicholas A Johnson; Guiseppe Garcea; Christopher P Neal; Ashley R Dennison; David P Berry
Journal:  ANZ J Surg       Date:  2009-06       Impact factor: 1.872

3.  Pancreatic adenocarcinoma versus chronic pancreatitis: differentiation with triple-phase helical CT.

Authors:  Yasunari Yamada; Hiromu Mori; Shunro Matsumoto; Hiro Kiyosue; Yuko Hori; Norio Hongo
Journal:  Abdom Imaging       Date:  2010-04

4.  Pancreatic carcinoma versus chronic focal pancreatitis: contrast-enhanced power Doppler ultrasonography findings.

Authors:  M Scialpi; M Midiri; T V Bartolotta; M P Cazzolla; A Rotondo; M C Resta; R Lagalla; A E Cardinale
Journal:  Abdom Imaging       Date:  2005-12-30

5.  Quality of life and outcomes after pancreaticoduodenectomy.

Authors:  J J Huang; C J Yeo; T A Sohn; K D Lillemoe; P K Sauter; J Coleman; R H Hruban; J L Cameron
Journal:  Ann Surg       Date:  2000-06       Impact factor: 12.969

6.  Role of fine needle aspiration cytology and endoscopic biopsy in the preoperative assessment of pancreatic and peripancreatic malignancies.

Authors:  R Nakamura; R Machado; K Amikura; B Ruebner; C F Frey
Journal:  Int J Pancreatol       Date:  1994-08

7.  Tissue diagnosis for carcinoma of the pancreas and periampullary structures.

Authors:  Y T Lee
Journal:  Cancer       Date:  1982-03-01       Impact factor: 6.860

8.  Palliative surgical bypass for unresectable periampullary carcinoma.

Authors:  Shivendra Singh; Ajay Kumar Sachdev; Adarsh Chaudhary; Anil Kumar Agarwal
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2008-06

9.  Surgical management of unresectable carcinoma of the pancreas.

Authors:  M G Sarr; J L Cameron
Journal:  Surgery       Date:  1982-02       Impact factor: 3.982

10.  Soluble interleukin-2 receptor: a new marker in pancreatic adenocarcinoma?

Authors:  P G Rabitti; L Pacelli; G Uomo; M Laccetti; O A Spada; G Esposito; M Visconti
Journal:  Minerva Gastroenterol Dietol       Date:  1994-09
View more
  3 in total

1.  Surgically proved visually isoattenuating pancreatic adenocarcinoma undetected in both dynamic CT and MRI. Was blind pancreaticoduodenectomy justified?

Authors:  Konstantinos Blouhos; Konstantinos A Boulas; Dimitrios G Tselios; Stavroula P Katsaouni; Basiliki Mauroeidi; Anestis Hatzigeorgiadis
Journal:  Int J Surg Case Rep       Date:  2013-02-24

2.  Double Duct to Mucosa Pancreaticojejunostomy for Bifid Pancreatic Duct following Pylorus Preserving Pancreaticoduodenectomy: A Case Report.

Authors:  K Vasiliadis; C Papavasiliou; N Lamprou; P Delivorias; S Papaioannou; A Karagiannidis; C Makridis
Journal:  Case Rep Med       Date:  2012-12-05

3.  Endoscopic ultrasound-guided sampling in gastroenterology: European society of gastrointestinal endoscopy technical guidelines.

Authors:  Christoph F Dietrich; C Jenssen
Journal:  Endosc Ultrasound       Date:  2013-07       Impact factor: 5.628

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.